Scaling Up Cell Therapy Manufacturing in Guangzhou
GE Healthcare FlexFactory Helps XPH Scale Up Industrialization of TCR T Cell Immunotherapy Drugs.
In March 2019, Xiangxue Pharmaceutical Co., Ltd. (XPH) will be ready to manufacture TCR T Cell therapies in Guangzhou, China. Continuing the country’s rapidly growing leadership in the cell therapy industry, XPH announced it will install a FlexFactory™ for cell therapy, a semi-automated end-to-end manufacturing platform, to help scale up, digitize and accelerate manufacturing processes for their cell therapy clinical trials and future commercialization.
This project marks the first-ever application of FlexFactory for cell immunotherapy drugs based on high-affinity and high-specificity T Cell receptors (TCR). XPH aims to deliver a breakthrough for cancer treatment with a new-generation TCR T Cell therapy, and has become one of the industry-leading companies to roll out related research for this application.
Cell therapy is recognized as one of the most promising models for comprehensive and precise cancer treatment. But the manufacturing process is complex and it is a challenge for companies to produce cell therapies at industrial scale. Thus, FlexFactory for cell therapy was developed to help companies achieve stable, safe and scalable manufacturing of cell therapy products. The platform helps shorten the commercialization cycle through accelerated translation from scientific research to clinical trials to industrial-scale production. Along with the manufacturing platform, GE Healthcare Life Sciences will also provide XPH with training services, process development, flexible cell processing equipment and digital connectivity solutions.
With a high concentration of healthcare companies and medical resources, Guangzhou is currently implementing the IAB Plan to advance development in information technology, AI, and biotechnology industries. GE Healthcare and XPH are committed to creating a world-leading cell therapy manufacturing platform in the Guangzhou Development Zone. Thus, this close strategic partnership helps establish a new world-leading bioindustry ecosystem in Guangzhou.
To read the full press release, click here: GE Healthcare FlexFactory Helps XPH Scale Up Industrialization of TCR T-Cell Immunotherapy Drugs